The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/II study of MM-111, a novel bispecific antibody that targets the ErB2/ErB3 heterodimer, in combination with trastuzumab in advanced refractory HER2-positive breast cancer.
M. J. Higgins
Consultant or Advisory Role - Merrimack (U)
N. Y. Gabrail
No relevant relationships to disclose
K. Miller
Research Funding - Merrimack
S. V. Agresta
Employment or Leadership Position - Merrimack
Stock Ownership - Merrimack
S. Sharma
No relevant relationships to disclose
C. McDonagh
Employment or Leadership Position - Merrimack
Stock Ownership - Merrimack
J. Murray
Employment or Leadership Position - Merrimack
Stock Ownership - Merrimack
K. Andreas
Employment or Leadership Position - Merrimack
S. Frye
Employment or Leadership Position - Merrimack
V. M. Moyo
Employment or Leadership Position - Merrimack
Stock Ownership - Merrimack
C. Niyikiza
Employment or Leadership Position - Merrimack
Stock Ownership - Merrimack
P. D. Ryan
No relevant relationships to disclose